<DOC>
	<DOCNO>NCT01896271</DOCNO>
	<brief_summary>In i-SABR ( immunotherapy + Stereotactic Ablative Body Radiation ) trial , stereotactic radiation multiple metastatic site deliver eradicate site bulky progressive disease , also provide antigen presentation immune stimulation expect act synergistically immediately follow non-specific immune stimulation provide treatment HD IL-2 thereby increase response rate complete response metastatic clear cell renal cell cancer patient . Both HD IL-2 SABR FDA approve therapeutic cancer treatment</brief_summary>
	<brief_title>High Dose IL-2 Stereotactic Ablative Body Radiation Therapy Metastatic Renal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>1 . Biopsyproven metastatic clear cell RCC . 2 . Radiographic evidence metastatic disease . 2.1 Patients number metastatic site allow enroll . However , six site select SBRT treatment , discretion treat radiation oncologist . 3 . Patient must ≥1 lesion size &gt; 1.5cm . 4 . Previous treatment surgery , radiation , chemotherapy , immunotherapy target agent allow 28 day start HD IL2 5 . Age ≥ 18 year . 6 . Performance status ECOG 0 , 1 . 7 . Patient must eligible HD IL2 treatment 8 . Patient must eligible SABR one extra cranial site . 9 . Adequate organ marrow function define : leukocyte ≥ 3,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 50,000/mcl total bilirubin ≤ 2mg/dL AST ( SGOT ) /ALT ( SPGT ) ≤ 2.5 X institutional upper limit normal 10 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 10.1 A female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has undergone hysterectomy bilateral oophorectomy ; Has naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 11 . Ability understand willingness sign write informed consent 12 . Adequate Renal function Cr ≤ 1.6 mg/dL . 13 . Adequate cardiac function ( adequate perfusion ; ischemia ) thallium ( Tc ) stress test 14 . Adequate pulmonary function PFT ( FEV1 &gt; 65 % ; DLCO &gt; 60 % ) . 1 . Subjects chemotherapy radiotherapy within 4 week prior enter study 2 . History HIV , Hepatitis B , Hepatitis C HTLV serology 3 . Subjects may receive investigational standard antineoplastic agent . 4 . Subjects know brain metastasis exclude clinical trial poor prognosis 5 . Subjects life expectancy &lt; 6 month . 6 . History allergic reaction recombinant IL2 7 . Uncontrolled recurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , . 8 . Psychiatric illness/social situation would limit compliance study requirement . 9 . Subjects must pregnant nursing due potential congenital abnormality potential regimen harm nursing infant . 10 . Systemic topical steroid use immunosuppressive therapy within past 28 day 11 . Subjects require take corticosteroid immunosuppressive therapy organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>kidney cancer</keyword>
	<keyword>metastatic cancer</keyword>
</DOC>